
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate Inc. is strategically positioned in the growing ADHD medication market, which has experienced approximately 8% annual growth, reaching around $18 billion in 2020, indicating a strong demand for its products. The company is advancing its proprietary medications, CTx-1301 and CTx-1302, with expected approval and commercialization timelines around mid to late-2026, presenting potential catalysts for significant stock value appreciation. Additionally, the current valuation of Cingulate's stock is considered attractive, reflecting an opportunity where the risk versus reward dynamic remains favorable amid the overall market potential for ADHD treatments.
Bears say
Cingulate Inc reported a net loss of $7.3 million, representing an earnings per share (EPS) of $(1.35), which was significantly worse than both internal estimates of $(0.79) and consensus expectations of $(0.81). Additionally, the company's prior net loss of $6.5 million, with an EPS of $(0.93), also fell short of estimated and consensus figures. The company faces several notable risks, including liquidity challenges, potential failures in clinical trial outcomes for its product candidates, regulatory approval obstacles, and competitive pressures, all of which underscore a negative outlook for its financial stability and stock performance.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares